ArticleProceedings of the National Academy of Sciences of the United States of America2026
DeepDegradome: A structure-aware deep learning framework for PROTAC and ligand generation against protein targets.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Cyclins and Cyclin-Dependent Kinases: Structure, Biological Functions, and Innovative Targeting Strategies in Cancer.MedComm · 2026Review
- Ubiquitin-Dependent Regulation of Influenza A Virus Polymerase and vRNP Function: Mechanisms and Therapeutic Opportunities.Microorganisms · 2026Review
- Design of Synthesizable PROTACs through Synthesis Constrained Generative Model and Reinforcement Learning.JACS Au · 2026Article
- DeepDegradome: A structure-aware deep learning framework for PROTAC and ligand generation against protein targets.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Targeted protein degradation is a promising strategy for drug discovery, but designing effective PROTACs remains challenging, especially for proteins without well-defined binding sites. Current methods rely on modifying linkers between fixed ligands, which limits the diversity and innovation of the overall molecular architecture of PROTAC. Here, we introduce DeepDegradome, an AI-powered method that automates the structure-aware design of both small-molecule ligands and PROTACs. It employs a large fragment library constructed from public databases and applies an in-house docking method (iFitDock) to obtain initial binding fragments. DeepDegradome builds ligands by assembling these fragments based on the shape and physicochemical features of the target protein pocket. It can further construct PROTACs from these generated ligands, eliminating the dependency on predefined warheads or E3 ligands. Compared to other AI models, DeepDegradome produces more valid, drug-like molecules with higher predicted binding affinity. We demonstrate DeepDegradome's effectiveness by designing and validating multiple potency inhibitors and PROTACs for two protein targets: WDR5 and CDK9. One synthesized compound showed excellent agreement between predicted and actual binding conformation confirmed by X-ray crystallography. By combining ligand and PROTAC design in one system, DeepDegradome offers a scalable and reliable tool for discovering new drugs against protein targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.